Literature DB >> 19037255

Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy.

Rosanna Coppo1, Roberta Camilla, Alda Alfarano, Sabrina Balegno, Domenico Mancuso, Licia Peruzzi, Alessandro Amore, Antonio Dal Canton, Vincenzo Sepe, Pierangelo Tovo.   

Abstract

In order to present an antigen to T-cells, the antigen must first be degraded by proteasomes. Following exposure to interferons, some proteasome subunits (ss1,ss2,ss5) are replaced by others (LMP2, LMP7, MECL-1) that have more optimal catalytic properties for peptide presentation; this more efficient organelle is termed the immuno-proteasome. Here we measured gene expression of various subunits in peripheral mononuclear cells of patients with IgA nephropathy, a disease with features of immune dysregulation. We used quantitative PCR to measure the expression of proteasomal subunit mRNA in mononuclear cells from IgA nephropathy patients, a group of proteinuric control patients with idiopathic nephrotic syndromes, and healthy controls. A significant switch in the expression of trypsin- and chymotrypsin-like proteasome subunits to corresponding immuno-proteasome subunits was found in patients as compared to healthy controls. Further, we found that nuclear translocation of NF-kappaB p50 and p65 was significantly greater in the IgA nephropathy patients, but this did not correlate with the switch to the immuno-proteasome phenotype. Patients with proteinuria greater than 0.5 g/1.73 m(2)/day had a significant switch of the chymotryptic-like beta5 protease to the LMP7 subunit, but this did not occur in patients with idiopathic nephrotic syndrome. The switch to an immuno-proteasome in peripheral blood mononuclear cells of patients with IgA nephropathy suggests an increased efficiency of antigen processing and presentation. This switch appears to be independent of a coincidental activation of the NF-kappaB pathway but is associated with high levels of proteinuria, a well known risk factor for progression of IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037255     DOI: 10.1038/ki.2008.579

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

1.  Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy.

Authors:  Maria Elena Donadio; Elisa Loiacono; Licia Peruzzi; Alessandro Amore; Roberta Camilla; Federica Chiale; Luca Vergano; Alberto Boido; Margherita Conrieri; Manuela Bianciotto; Francesca Maria Bosetti; Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2014-04-01       Impact factor: 3.714

2.  Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Authors:  Luca Vergano; Elisa Loiacono; Roberto Albera; Rosanna Coppo; Roberta Camilla; Licia Peruzzi; Alessandro Amore; Maria Elena Donadio; Federica Chiale; Alberto Boido; Filippo Mariano; Gianna Mazzucco; Sara Ravera; Giovanni Cancarini; Riccardo Magistroni; Giulietta Beltrame; Cristiana Rollino; Piero Stratta; Marco Quaglia; Roberto Bergia; Raffaella Cravero; Stefano Cusinato; Luisa Benozzi; Silvana Savoldi; Carola Licata
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 3.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

Review 4.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

Review 5.  The genetics and immunobiology of IgA nephropathy.

Authors:  Krzysztof Kiryluk; Jan Novak
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 6.  Biomarkers and targeted new therapies for IgA nephropathy.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2016-06-20       Impact factor: 3.714

7.  Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-01-06

8.  MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B.

Authors:  Rui Wang; Zigang Zhao; Liqiang Zheng; Xiaojing Xing; Wei Ba; Junfen Zhang; Min Huang; Wenwei Zhu; Bing Liu; Xianfu Meng; Jia Bai; Chengxin Li; Hengjin Li
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

9.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

Review 10.  Genetic studies of IgA nephropathy: what have we learned from genome-wide association studies.

Authors:  Jingyuan Xie; Samantha Shapiro; Ali Gharavi
Journal:  Contrib Nephrol       Date:  2013-05-08       Impact factor: 1.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.